Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

News Daily News

Air Pollution Contributes to CV Death Regardless of Race or Ethnicity

L.A. McKeown

December 19, 2017

Presentation TCT 2017

Perspectives on the Feasibiity and Trustworthiness of Large, Simple Trials: From TASTE to ADAPTABLE

Presenter: Robert A. Harrington, Sanjay Kaul, Schuyler Jones

October 30, 2017

Presentation TCT 2017

Risk Score Development, Validation, Precision, Discrimination, and Utility

Presenter: Robert A. Harrington, Sanjay Kaul, Davide Capodanno

October 30, 2017

Presentation TCT 2017

Do Patients Really Do Better When Their Cardiologists Are Away at Conferences? Embedding Controls in Observational Studies

Presenter: Robert A. Harrington, Sanjay Kaul, Robert W. Yeh

October 30, 2017

Presentation TCT 2017

Assessment of the Quality and Reliability of Meta-analysis (Summary Level, Network, and Individual Patient Data-Based)

Presenter: Robert A. Harrington, Sanjay Kaul, Giuseppe Biondi-Zoccai

October 30, 2017

Presentation TCT 2017

Natures Randomized Trials: Natural Experiments, Instrumental Variables, and Mendelian Randomization (Strengths and Limitations)

Presenter: Robert A. Harrington, Sanjay Kaul, Robert W. Yeh

October 30, 2017

Presentation TCT 2017

The Worst Misinterpretations Ive Seen in Observational Research Studies: How to Spot Them, How to Avoid Them

Presenter: Robert A. Harrington, Sanjay Kaul

October 30, 2017

Presentation TCT 2017

Topic 4: At the Cusp of Diminishing Returns for CV Therapies - Personalized Approaches and New Frontiers

Presenter: Robert A. Byrne, Gregg W. Stone, Robert A. Harrington

October 30, 2017

Presentation TCT 2017

Topic 3: Chronic Total Occlusion PCI - What Level of Evidence Is Required for Widespread Acceptance: Hard Endpoints vs QOL Measures

Presenter: Robert A. Byrne, Gregg W. Stone, J. Aaron Grantham

October 30, 2017

Presentation TCT 2017

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

Presenter: Robert A. Byrne, Gregg W. Stone, Robert A. Harrington

October 30, 2017

Presentation TCT 2017

Topic 1: How Should We Evaluate Technologies in Their Infancy? TAVR, Renal Denervation, BVS, LAA Closure, Mechanical Circulatory Support, and More

Presenter: Robert A. Byrne, Gregg W. Stone, Aaron V. Kaplan

October 30, 2017

Presentation TCT 2017

Alternatives to Traditional P-value Testing: Bayesian Designs

Presenter: Eugene H. Blackstone, Stuart J. Pocock, Roseann M White

October 30, 2017

Presentation TCT 2017

Beyond Time-to-First Event: Counting Multiple Events, Hierarchical Measures, and Weighted Composites

Presenter: Eugene H. Blackstone, Stuart J. Pocock, Jan G. P. Tijssen

October 30, 2017

Presentation TCT 2017

Proper and Improper Interpretations of the P-value

Presenter: Eugene H. Blackstone, Stuart J. Pocock

October 30, 2017

Presentation TCT 2017

Strengths and Limitations of Composite Endpoints (eg, EXCEL, PLATO, and Others)

Presenter: Roxana Mehran, Robert W. Yeh, Stuart J. Pocock

October 30, 2017

Presentation TCT 2017

How to Interpret Trials That Are Stopped Early (eg, PRAMI, FAME II, DECISION CTO, and Others)

Presenter: Roxana Mehran, Robert W. Yeh, Laura Mauri

October 30, 2017

Presentation TCT 2017

How to Interpret Noninferiority Trials (eg, ABSORB III, EVEREST II, and Others)

Presenter: Roxana Mehran, Robert W. Yeh, Sanjay Kaul

October 30, 2017

News Daily News

Sky-High US Obesity Rates Aren’t Coming Down

Todd Neale

October 13, 2017

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Todd Neale

September 15, 2017

News Daily News

Study Links Marijuana Use to Hypertension-Related Death

Ashley Lyles

August 10, 2017

Advertisement

Air Pollution Contributes to CV Death Regardless of Race or Ethnicity

Perspectives on the Feasibiity and Trustworthiness of Large, Simple Trials: From TASTE to ADAPTABLE

Risk Score Development, Validation, Precision, Discrimination, and Utility

Do Patients Really Do Better When Their Cardiologists Are Away at Conferences? Embedding Controls in Observational Studies

Assessment of the Quality and Reliability of Meta-analysis (Summary Level, Network, and Individual Patient Data-Based)

Natures Randomized Trials: Natural Experiments, Instrumental Variables, and Mendelian Randomization (Strengths and Limitations)

The Worst Misinterpretations Ive Seen in Observational Research Studies: How to Spot Them, How to Avoid Them

Topic 4: At the Cusp of Diminishing Returns for CV Therapies - Personalized Approaches and New Frontiers

Topic 3: Chronic Total Occlusion PCI - What Level of Evidence Is Required for Widespread Acceptance: Hard Endpoints vs QOL Measures

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

Topic 1: How Should We Evaluate Technologies in Their Infancy? TAVR, Renal Denervation, BVS, LAA Closure, Mechanical Circulatory Support, and More

Alternatives to Traditional P-value Testing: Bayesian Designs

Beyond Time-to-First Event: Counting Multiple Events, Hierarchical Measures, and Weighted Composites

Proper and Improper Interpretations of the P-value

Strengths and Limitations of Composite Endpoints (eg, EXCEL, PLATO, and Others)

How to Interpret Trials That Are Stopped Early (eg, PRAMI, FAME II, DECISION CTO, and Others)

How to Interpret Noninferiority Trials (eg, ABSORB III, EVEREST II, and Others)

Sky-High US Obesity Rates Aren’t Coming Down

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Study Links Marijuana Use to Hypertension-Related Death

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content